Survodutide (BI 456906) — Dosing, Cycles, Half-Life & Side Effects

Survodutide (BI 456906) is a GLP-1 receptor agonist with a half-life of 5-7 days. Dual GLP-1/glucagon receptor agonist in Phase III trials for obesity and MASH (metabolic-associated steatohepatitis). Shows up to 18.7% weight loss and significant liver fat reduction. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

IMPORTANT DISCLAIMER – NO DOCTOR-PATIENT RELATIONSHIP

Use of this Service, including any AI-generated responses, cycle recommendations, lab result analysis, risk assessments, or shared user content, does not create a doctor-patient, therapist-patient, or any other professional-client relationship. The information provided is for educational, informational, and harm-reduction purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment from a licensed physician. Never disregard professional medical advice or delay in seeking it because of something you have read or generated on this platform. If you have a medical emergency, call 911 (US) or your local emergency number immediately. Always consult your physician or other qualified healthcare provider with any questions regarding your health, medications, or cycle protocols. The operators of this platform are not licensed medical professionals and do not practice medicine.

Quick Facts

Class	GLP-1 Agonists
Half-life	5-7 days
Hepatotoxicity	None
Suppression	0/10

Typical Dosing Ranges

Common dose range: 0.6-4.8mg weekly (titrated)

Cycle length: 24-52+ weeks

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.

PCT Requirements

Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

Not yet approved
GI side effects common
Nausea, vomiting, diarrhea
Dose titration required
Limited long-term data

Known Interactions

No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry.

Monitoring (Bloodwork & Vitals)

Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
Lipid panel (total cholesterol, HDL, LDL, triglycerides)
CBC (hemoglobin, hematocrit — watch for erythrocytosis)
Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of Survodutide (BI 456906)?

Survodutide (BI 456906) has a half-life of approximately 5-7 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for Survodutide (BI 456906)?

Commonly reported ranges for Survodutide (BI 456906): 0.6-4.8mg weekly (titrated). Cycle length: 24-52+ weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does Survodutide (BI 456906) suppress natural testosterone?

Survodutide (BI 456906) causes minimal suppression of the HPTA axis (score 0/10). PCT may still be advisable depending on stack and duration.

What is Survodutide (BI 456906) typically used for?

Survodutide (BI 456906) is commonly used for: Obesity (investigational), MASH/fatty liver, Metabolic syndrome. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Is Survodutide (BI 456906) legal?

Survodutide (BI 456906) is a controlled substance in many jurisdictions (typically Schedule III in the US when it is an anabolic androgenic steroid). StackItSmart does not provide sourcing information. Possession, import, and use without a prescription carry legal consequences that vary by country and state.

Citations

Frias JP et al.. 2023. Lancet — Survodutide dual agonist (GLP-1/glucagon) Phase 2 MASH trial data

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Survodutide (BI 456906). Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.